InsiderTrades

Form 4 for TRVI Trevi Therapeutics, Inc.

Accepted 2024-05-14 00:00:00 ET · period of report 2024-05-10 · accession 0000950170-24-059722 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-05-14 2024-05-10 TRVI GOOD JENNIFER L Pres, CEO, Dir S - Sale+OE $2.90 -4,578 213.3K -2% -$13.3K
D 2024-05-14 2024-05-10 TRVI GOOD JENNIFER L Pres, CEO, Dir M - OptEx $2.19 +4,578 217.9K +2% +$10.0K
D 2024-05-14 2024-05-10 TRVI GOOD JENNIFER L Pres, CEO, Dir M - OptEx $0.00 -4,578 58.2K -7% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-05-10 S D 4,578 $2.90 213,313 D — — (F1) Includes 7,109 shares purchased through the Issuer's employee stock purchase plan.
2 Common Common Stock 2024-05-10 M A 4,578 $2.19 217,891 D — — (F1) Includes 7,109 shares purchased through the Issuer's employee stock purchase plan.
3 Derivative Stock Option (right to buy) 2024-05-10 M D 4,578 $0.00 58,226 D $2.19 · — to 2024-07-01 4,578 Common Stock (F2) This option was granted on July 2, 2014. The 62,804 shares of common stock underlying the option vested as to 25% of the shares on June 11, 2015 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through June 11, 2018.